Vertex provides updates on phase 1/2 clinical trial of vx-880 for the treatment of type 1 diabetes

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today provided updates on its phase 1/2 clinical trial of vx-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (t1d) with impaired hypoglycemic awareness and severe hypoglycemia. two patients in part a received vx-880 at half the target dose. the first patient dosed in part a of the study achieved insulin independence at day 270, wit
VRTX Ratings Summary
VRTX Quant Ranking